Search results
Results from the WOW.Com Content Network
Trifluoromethyldeschloroketamine (TFMDCK) is a designer drug from the arylcyclohexylamine family, which is presumed to have similar properties to ketamine, a ...
Interestingly, recent studies indicate that children diagnosed with DMDD are 12.5% more likely to be prescribed any psychoactive medication, and 7.9% more likely to be prescribed an antipsychotic medication than children diagnosed with bipolar disorder. [29] At this time, DMDD does not have a standardized treatment course as few treatment ...
5-Trifluoromethyl-2-aminoindane (TAI) is a drug of the 2-aminoindane group with putative entactogenic effects. It functions as a selective serotonin releasing agent (SSRA). TAI is the aminoindane analogue of norfenfluramine and is approximately 50% as neurotoxic in comparison.
Trifluperidol is a typical antipsychotic of the butyrophenone chemical class.It has general properties similar to those of haloperidol, but is considerably more potent by weight, and causes relatively more severe side effects, especially tardive dyskinesia and other extrapyramidal effects.
Lumateperone was approved for medical use in the United States in December 2019 with an initial indication for schizophrenia, [4] [5] and became available in February 2020. [2] It has since demonstrated efficacy in bipolar depression and received FDA approval in December 2021 for depressive episodes associated with both bipolar I and II disorders.
The US Food and Drug Administration approved a novel tool Tuesday that uses genetic testing to help assess whether certain people are at risk of developing opioid use disorder.
Centanafadine (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical.
The U.S. FDA has approved privately held Italfarmaco Group's drug to treat Duchenne muscular dystrophy (DMD), an inherited muscle-wasting disorder, the health regulator said on Thursday. The oral ...